Logo
x

Search

Subscribe Now

Genentech

Genentech Reports Data from P-III (BALATON and COMINO) Trials of Vabysmo (faricimab-svoa) for Macular Edema due to Retinal Vein Occlusion

Genentech Reports Data from P-III (BALATON and COMINO) Trials of Vabysmo (faricimab-svoa) for Macular Edema due to Retinal Vein Oc...

  • February 1, 2024
Genentech Reports the Results of Inavolisib Combination Therapy in P-III Trial for the Treatment of Breast Cancer

Genentech Reports the Results of Inavolisib Combination Therapy in P-III Trial for the Treatment of Breast Cancer

  • December 5, 2023
Genentech’s Vabysmo (faricimab-svoa) Receives the US FDA’s Approval for the Treatment of Retinal Vein Occlusion

Genentech’s Vabysmo (faricimab-svoa) Receives the US FDA’s Approval for the Treatment of Retinal Vein Occlusion

  • October 27, 2023
PharmaShots Weekly Snapshots (October 09–13, 2023) _

PharmaShots Weekly Snapshots (October 09–13, 2023) _

  • October 14, 2023
Genentech Reports P-III Study (OCARINA II) Results of Ocrevus for the Treatment of Multiple Sclerosis

Genentech Reports P-III Study (OCARINA II) Results of Ocrevus for the Treatment of Multiple Sclerosis

  • October 12, 2023
Genentech Reports the US FDA Acceptance of BLA for Crovalimab to Treat Paroxysmal Nocturnal Hemoglobinuria

Genentech Reports the US FDA Acceptance of BLA for Crovalimab to Treat Paroxysmal Nocturnal Hemoglobinuria

  • September 6, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.